A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment

References

• Heit JA, Michael O’Fallon W, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162(11):1245–1248.
   PubMedGoogle Scholar
• Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–464.
   PubMed Web of Science ®Google Scholar
• Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using medicare claims data. Medicine (Baltimore). 1999;78(5):285–291.
   PubMed Web of Science ®Google Scholar
• Lyman GH. Venous thromboembolism in the patient with cancer. Cancer. 2011;117(7):1334–1349.
   PubMed Web of Science ®Google Scholar
• Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712–1723. [ American Society of Hematology].
   PubMed Web of Science ®Google Scholar
• Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11):1493–1505.
   PubMed Web of Science ®Google Scholar
• Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160(6):761–768.
   PubMed Web of Science ®Google Scholar
• Boccaccio C, Comoglio PM. Genetic link between cancer and thrombosis. J Clin Oncol. 2009;27:4827–4833.
   PubMed Web of Science ®Google Scholar
• Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117(2):219–230.
   PubMed Web of Science ®Google Scholar
• Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol. 2009;22(1):9–23.
   PubMed Web of Science ®Google Scholar
• Ahlbrecht J, Dickmann B, Ay C, et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2012;30(31):3870–3875.
   PubMed Web of Science ®Google Scholar
• Ku GH, White RH, Chew HK, et al. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood. 2009;113(17):3911–3917.
   PubMed Web of Science ®Google Scholar
• Semrad TJ, O’Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106(4):601–608.
   PubMed Web of Science ®Google Scholar
• White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90(3):446–455.
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Hagiwara M, Taneja C, et al. Risk of venous thromboembolism among hospitalized medically ill patients. Am J Heal Pharm. 2006;63(20 SUPPL)
   PubMed Web of Science ®Google Scholar
• Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118(5):555–568.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. N Engl J Med. 2008;358(1):36–46.
   PubMed Web of Science ®Google Scholar
• Couturier M-A, Huguet F, Chevallier P, et al. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l asparaginase: the GRAALL experience. Am J Hematol. 2015;90(11):986–991. .
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol. 1996;14(10):2731–2737.
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277–2285. JAMA.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. American Medical Association 2008;299: 914–924.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–2346.
   PubMed Web of Science ®Google Scholar
• Blom JW, Doggen CJM, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Assoc. 2005;293(6):715–722.
   PubMed Web of Science ®Google Scholar
• Khorana A, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy- associated thrombosis. Blood. 2008;111(10):4902–4907.
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–5382.
   PubMed Web of Science ®Google Scholar
• Pabinger I, Van Es N, Heinze G, et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018;5(7):e289–98.
   PubMed Web of Science ®Google Scholar
• Lee AYY, Levine MN, Baker RI, et al. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2003;349(2):146–153.
   PubMed Web of Science ®Google Scholar
• Raskob GE, Van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018;378(7):615–624.
   PubMed Web of Science ®Google Scholar
• Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism [Internet]. Blood. 2014;124(7):1020–1028. American Society of Hematology:
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023.
   PubMed Web of Science ®Google Scholar
• McBane RD, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–421.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020;382(17):1599–1607.
   PubMed Web of Science ®Google Scholar
• Giustozzi M, Agnelli G, Del Toro-Cervera J. et al. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: a Systematic Review and Meta-Analysis. Thromb Haemost. 2020;120(7):1128–1136. Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1712098.
   PubMed Web of Science ®Google Scholar
• Mulder FI, Bosch FTM, Young AM, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood. 2020;136(12):1433–1441.
   PubMed Web of Science ®Google Scholar
• Prandoni P, AWA L, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–3488.
   PubMed Web of Science ®Google Scholar
• Angelini DE, Radivoyevitch T, McCrae KR, et al. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol. 2019;94(7):ajh.25494.
   PubMed Web of Science ®Google Scholar
• Monreal M, Falgá C, Valdés M, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2006;4(9):1950–1956.
   PubMed Web of Science ®Google Scholar
• Testa S, Legnani C, Antonucci E, et al. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulant. J Thromb Haemost. 2019;17(7):1064–1072.
   PubMed Web of Science ®Google Scholar
• Kreutz R, Persson PB, Kubitza D, et al. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. J Thromb Haemost. 2017;15(10):2017–2028.
   PubMed Web of Science ®Google Scholar
• Hanigan MH, Dela Cruz BL, Thompson DM, et al. Use of Prescription and Non-Prescription Medications and Supplements by Cancer Patients during Chemotherapy; Questionnaire Validation.
   Google Scholar
• Fda. Coumadin (warfarin sodium) tablets Label [Internet]. www.fda.gov/medwatch.
   Google Scholar
• Kanuri SH, Kreutz RP. Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. Jan 17;9(1):7.
   Web of Science ®Google Scholar
• Short NJ, Connors JM New Oral Anticoagulants and the Cancer Patient. Oncologist. 2014;19(1):82–93. https://pubmed.ncbi.nlm.nih.gov/24319019/
   PubMed Web of Science ®Google Scholar
• Mulder FI, Candeloro M, Kamphuisen PW, et al. The khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104(6):1277–1287.
   PubMed Web of Science ®Google Scholar
• Parker A, Peterson E, Lee AYY, et al. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer. J Thromb Haemost. 2018;16(7):1321–1326.
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.Intern Emerg Med. 2012 Jun;7(3):291–292.
   Google Scholar
• Cella CA, Di Minno G, Carlomagno C, et al. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: the ONKOTEV Study. Oncologist. 2017;22(5):601–608.
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Taher A, Abdel‐Razeq H, et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: the Prospective COMPASS–Cancer‐Associated Thrombosis Study. Oncologist. 2017;22(10):1222–1231.
   PubMed Web of Science ®Google Scholar
• Ajm M, Ortega I, Font C, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 1056–61. Nature Publishing Group. DOI:10.1038/s41416-018-0027-8.
   Web of Science ®Google Scholar
• Sanfilippo KM, Luo S, Wang TF, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019;94(11):1176–1184.
   PubMed Web of Science ®Google Scholar
• Li A, Wu Q, Luo S, et al. Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. JNCCN J Natl Compr Cancer Netw. 2019;17(7):840–847.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.Lancet Oncol. 2009;Oct;10(10):943-9 www.thelancet.com/
   Google Scholar
• Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer. N Engl J Med. 2012;366(7):601–609.
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019;380(8):711–719.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019;380(8):720–728.
   PubMed Web of Science ®Google Scholar
• Agnelli G Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. N Engl J Med. 2019;380(8):781–783. http://www.nejm.org/doi/10.1056/NEJMe1816060
   PubMed Web of Science ®Google Scholar